Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

PHASE2CompletedINTERVENTIONAL
Enrollment

3,350

Participants

Timeline

Start Date

September 22, 2006

Study Completion Date

January 30, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix

BIOLOGICAL

adjuvanted influenza vaccine

Trial Locations (30)

1319

GSK Investigational Site, Bekkestua

2301

GSK Investigational Site, Hamar

2408

GSK Investigational Site, Elverum

5231

GSK Investigational Site, Paradis

5507

GSK Investigational Site, Haugesund

9000

GSK Investigational Site, Ghent

10365

GSK Investigational Site, Berlin

10367

GSK Investigational Site, Berlin

12601

GSK Investigational Site, Poughkeepsie

12687

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13507

GSK Investigational Site, Berlin

15106

GSK Investigational Site, Carnegie

15236

GSK Investigational Site, Pittsburgh

15562

GSK Investigational Site, Rüdersdorf

16506

GSK Investigational Site, Erie

33134

GSK Investigational Site, Coral Gables

33761

GSK Investigational Site, Clearwater

45229

GSK Investigational Site, Cincinnati

55318

GSK Investigational Site, Chaska

83527

GSK Investigational Site, Haag

84085

GSK Investigational Site, Langquaid

85635

GSK Investigational Site, Höhenkirchen-Siegertsbrunn

86150

GSK Investigational Site, Augsburg

88605

GSK Investigational Site, Messkirch

01757

GSK Investigational Site, Milford

08244

GSK Investigational Site, Somers Point

04129

GSK Investigational Site, Leipzig

N-1601

GSK Investigational Site, Fredrikstad

N-03730

GSK Investigational Site, Skien

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY